Latest hepatocellular carcinoma News

Seven Early-Career Scientists will Attend the AACR Annual Meeting with Ludwig Support
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Five Ludwig Cancer Research scientists named Fellows of the American Association for Cancer Research
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
New treatment offers hope for advanced liver cancer
New discovery for treatment of primary liver cancer
Aspartame hazard and risk assessment results released
Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four…
Manchester researchers awarded £1 million to test potential life-saving technology for early detection of liver cancer
Cancer Council welcomes the first Roadmap to Liver Cancer Control and Clinical Guidelines
5 things to know about liver cancer
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
New tests seek to predict liver cancer relapse and improve survival rates
Baylor receives more than $5.8 million in CPRIT funding
Dramatic rise in liver cancer in Australia’s tropical and equatorial north
Positive CHMP Opinion Etranacogene Dezaparvovec
CSL’s Novel Gene Therapy HEMGENIX Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living
U.S. Food and Drug Administration approves CSL’s HEMGENIX , first gene therapy for hemophilia B
Imjudo in combination with Imfinzi approved in US for patients with unresectable liver cancer
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
New molecular subset of pediatric liver cancer identified
Tremelimumab accepted under Priority Review in US for patients with unresectable liver cancer
Trialling non-invasive liver cancer treatment
AGA recommends shared decision-making approach for treatment of hepatocellular carcinoma
Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data
Targeting Stem Cell Signaling Could Halt Liver Cancer Progression Elucidating novel therapeutic target
New Curtin-led research aims to reduce stillbirth among Aboriginal families
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial
International experts develop Clinical Care Pathway in response to NASH epidemic
New funding to support innovative medical research
New medicines for Australians with multiple sclerosis, lymphoma, carcinoma and reproductive cancers
New medicines for Australians with multiple sclerosis, lymphoma, carcinoma and reproductive cancers
Even mild fatty liver disease is linked to increased mortality
Investment in liver cancer medicines matched with prevention are changing Australian lives
Budget 2020-21: Record health and aged care investment under Australia’s COVID-19 pandemic plan
Budget to deliver better access to life changing medicines for liver cancer, eye conditions and Parkinson’s disease
Laser-welded sugar: Sweet way to 3D-print blood vessels
New AGA guidance addresses cancer screening in NAFLD patients
More than $47 million awarded to Monash University for vital medical research
Low-dose aspirin linked to reduced liver cancer risk